On November 25, GeLongHui reported that Anhui Anke Biotechnology (300009.SZ) recently received an administrative permit document from the State Food and Drug Administration, accepting the supplementary application of human growth hormone injection for indications of small for gestational age (SGA). The acceptance number is: CYSB2400303.
The goal of human growth hormone therapy for SGA is to accelerate the linear growth process of children in the early stage to achieve catch-up growth, maintain normal growth rate in the later stage of child growth and development, and ultimately reach normal adult height. Human growth hormone has been on the market for many years both domestically and internationally, and has been widely used in the treatment of SGA children with short stature.
The company's human growth hormone injection has the characteristics of no preservatives and convenient use. The addition of this indication enriches and supplements the 8 indications that the company's human growth hormone has already been approved for. If approved, it will help meet the clinical medication needs of such patients and enhance the company's market competitiveness.